Anti-HLA-A2 (Human) mAb (Monoclonal Antibody)

  • Applications
    • FCM
    • IHC
    • IP
  • Target HLA-A2
  • Host Species Mouse
  • Species Reactivities Human
  • Code # K0186-3
  • Size 100 μg
  • Price
    $233.93
Specifications

Background

Human leukocyte antigen-A2 (HLA-A2) is a class I molecule of the human major histocompatibility complex (MHC). It is a heterodimer composed of a 43 kDa α subunit that is non-covalently associated with the 12 kDa β2-microglobulin protein. HLA-A2, like other class I molecules, binds peptides from proteins degraded in the cytoplasm and plays a role in antigen presentation and interaction with CD8+ T cells. HLA-A2 is the most common HLA-A allele in the Caucasian and American Indian populations (~30% and 50%, respectively) and A2 restricted T cell epitopes have been studied widely.
  • Antibody Type:
    Monoclonal
  • Application:
    FCM, IHC, IP
  • Clone Number:
    BB7.2
  • Concentration:
    1 mg/mL
  • Conjugate:
    Unlabeled
  • Description:

    Monoclonal Antibody of 100 μg targeting HLA-A2 for FCM, IHC, IPP.

  • Formulation:
    1.0 mg/mL in PBS/50% glycerol, pH 7.2
  • Gene ID (Human):
  • Host Species:
    Mouse
  • Immunogen:
    HLA-A2 was solubilized with papain
  • Product Type:
    Antibody
  • Reactivity:
    This antibody reacts with HLA-A2 onImmunoprecipitation, Immunohistochemistry and Flowcytometry
  • Research Area:
    Cell Biology
  • Short Description:

    HLA-A2 Monoclonal Antibody.

     

  • Size:
    100 μg
  • Species Reactivity:
    Human
  • Storage Temperature:
    -20°C
  • Target:
    HLA-A2
Citations
  1. Kozako T et al. Reduced frequency, diversity, and function of human T cell leukemia virus type 1-specific CD8+ T cell in adult T cell leukemia patients. J Immunol. 177, 5718-26 (2006),
  2. Wu F et al. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy. Cancer Lett. 339, 195-207 (2013)
References
  1. Wu, H., et al., Cancer Lett. 339, 195-207 (2013)
  2. Kozako, T., et al., J. Immunol. 177, 5718-5726 (2006) [FCM]
  3. Yamano, Y., et al., J. Exp. Med. 199, 1367-1377 (2004)
  4. Rodolfo, M., et al., Cancer Res. 63, 6948-6955 (2003)
  5. Smith, M. E. F. et al., PNAS 86, 5557-5561 (1989)
  6. Parham, P., et al., Human Immunology 3, 277-299 (1981)